ProMetic Life Sciences vs. Actinium Pharmaceuticals: A Detailed Comparison

Small-cap medical companies ProMetic Life Sciences and Actinium Pharmaceuticals are under scrutiny as investors evaluate which firm offers greater potential for growth. A comprehensive comparison reveals key metrics across institutional ownership, analyst recommendations, profitability, risk, and earnings performance.

Risk and Volatility Analysis

Assessing volatility, ProMetic Life Sciences exhibits a beta of 2.46, indicating its share price is approximately 146% more volatile than the S&P 500. In stark contrast, Actinium Pharmaceuticals shows a beta of -0.3, making its shares around 130% less volatile than the same index. This significant difference in volatility may influence investor decisions, particularly those sensitive to market fluctuations.

Institutional and Insider Ownership

When it comes to ownership by institutional investors, ProMetic Life Sciences has only 0.1% of its shares held by these entities. On the other hand, Actinium Pharmaceuticals has a much stronger institutional backing, with 27.5% of its shares owned by institutional investors. Additionally, company insiders hold 0.6% of Actinium Pharmaceuticals shares. High institutional ownership often signals confidence among large investors regarding a company’s long-term growth.

Analyst ratings also reflect differing perspectives on the two companies. According to MarketBeat.com, the recommendations for both companies will further clarify their investment attractiveness.

Profitability and Earnings Comparison

Profitability metrics reveal that Actinium Pharmaceuticals outperforms ProMetic Life Sciences in terms of earnings. While Actinium has lower revenue figures, its earnings per share (EPS) are significantly higher. This discrepancy may indicate a more efficient operational performance or a more valuable product pipeline, which could attract investors looking for profitable ventures.

In summary, Actinium Pharmaceuticals surpasses ProMetic Life Sciences in 10 out of 12 evaluated factors. This trend may suggest that Actinium is poised for better long-term performance compared to its competitor.

Company Profiles

ProMetic Life Sciences, founded in 1992 and based in Laval, Canada, operates as a biopharmaceutical company focusing on unmet medical needs, particularly in fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an oral drug candidate aimed at treating fibrosis, and other significant treatments such as plasminogen for congenital plasminogen deficiency.

On the other hand, Actinium Pharmaceuticals, headquartered in New York, USA, specializes in developing antibody radiation conjugates and targeted radiotherapies for oncology patients who have not responded to existing treatments. Its flagship product, Iomab-B, serves as an induction and conditioning agent before bone marrow transplants in patients with relapsed acute myeloid leukemia. The company is also advancing Actimab-A, which shows promise for treating various myeloid malignancies.

As the market continues to evolve, the performance of these two companies will be closely monitored by investors and analysts alike. The contrasting profiles and operational metrics of ProMetic Life Sciences and Actinium Pharmaceuticals provide valuable insights into the small-cap biopharmaceutical landscape.